Hippocampal Atrophy in Alzheimer’s Disease Patients: Understanding the Research

April 12, 2022Henry Peck

Despite the vast prevalence of Alzheimer’s disease and Lewy body dementia and the continually growing understanding of their complex pathologies, their rates of misdiagnosis remain high, emphasizing the urgent need for more robust diagnostic criteria and/or better diagnostic tools. According to the 2021 World Alzheimer’s Report, up to 30% of people diagnosed with Alzheimer’s disease are misdiagnosed. Similarly, a survey by the Lewy Body Dementia Association revealed that nearly 80% of people with Lewy body dementia received a diagnosis for a different cognitive, movement, or psychiatric disorder, with the majority of misdiagnoses being attributed to Alzheimer’s disease.

Over the past two decades, hippocampal atrophy in Alzheimer’s disease has received increased attention in the research world for two primary reasons:

  • Hippocampal atrophy patterns may help distinguish between Lewy body dementia and Alzheimer’s disease.
  • Hippocampal atrophy has been identified as a possible predictor for the conversion from Mild Cognitive Impairment (MCI) to Alzheimer’s disease.

Below, we take a closer look at hippocampal atrophy in Alzheimer’s disease and Lewy body dementia, hippocampal atrophy as a possible predictor of conversion from MCI to Alzheimer’s disease, and address current diagnostic challenges.

Hippocampal Atrophy in Alzheimer’s disease and Lewy Body Dementia

The misdiagnoses of Alzheimer’s disease and Lewy body dementia are largely due to the wide clinical overlap between neurological diseases. Nearly 80% of individuals with Lewy body dementia will also present with brain changes consistent with Alzheimer’s disease, while nearly 40% of those with Alzheimer’s disease present with features of Lewy body dementia.

Consequently, clinical distinction between the two is often challenging, particularly during the early stages. Because of this, there is a need to either 1) improve diagnostic criteria or 2) utilize newer, more reliable diagnostic tools.

To address the former, researchers have been investigating hippocampal atrophy as a potential pathological characteristic to distinguish between Alzheimer’s and Lewy body dementia. When analyzing hippocampal atrophy patterns from magnetic resonance imaging (MRI) data from 113 subjects (55 AD, 16 LBD, and 42 cognitively normal elderly), researchers found that:

  • Compared to cognitively normal elderly individuals, those with (mild) Alzheimer’s disease showed significantly greater atrophy in the Cornu Ammonis (CA) 1, CA2-3, and subicular regions bilaterally.
  • Compared to cognitively normal elderly individuals, those with (mild) Lewy body dementia showed left-predominant atrophy in the CA1 region and subiculum.
  • Alzheimer’s and Lewy body dementia, when compared directly, did not show statistically significant differences.

While it appears hippocampal atrophy in Lewy body dementia is less severe than in Alzheimer’s disease, assessing this additional pathological characteristic may not be sufficient to reliably and accurately distinguish between the two.

Hippocampal Atrophy as Potential Predictor of Conversion to Alzheimer’s

While most patients with MCI transition to Alzheimer’s disease, others develop non-Alzheimer’s dementia, remain in the MCI state, or improve. Identifying patients with MCI who are more likely to progress to Alzheimer’s disease is a critical step in Alzheimer’s disease prevention. Over the years, many prognosis prediction models for conversion from MCI to Alzheimer’s disease have been proposed, from molecular subtyping-based prediction models and multi-predictor nomogram models to hippocampal atrophy models. 

Researchers have hypothesized that smaller hippocampal volumes may predict conversion from MCI to Alzheimer’s, while larger hippocampal volumes predict cognitive stability and/or improvement. A three-year longitudinal cohort study assessing this hypothesis concluded that smaller hippocampi, and specifically CA1 and subicular involvement, are associated with an increased risk of conversion from MCI to Alzheimer’s disease.

While hippocampal atrophy alone may not be able to predict conversion from MCI to Alzheimer’s, in the future, it may be used in conjunction with traditional biomarkers for Alzheimer’s disease, though doing so at scale may not be feasible given the growing number of Alzheimer’s cases and the immense cost of utilizing such diagnostic tools.

Addressing Diagnostic Challenges

Unfortunately, it is unclear if pathological characteristics, such as region-specific atrophy and protein levels (e.g. beta-amyloid and tau), directly correlate with the presence or severity of neurological diseases like Alzheimer’s and Lewy body dementia, meaning such measures may not be sufficient for reliable, accurate diagnoses. Moreover, while protein levels and atrophy patterns may correlate with neurocognitive decline to some degree, it is not necessarily a 1:1 relationship, making it difficult to utilize such data to place patients at a specific phase on a disease continuum.

Consequently, relying on pathology-based diagnostic tools, like MRI to assess atrophy or positron emission scans to measure protein levels, likely contributes heavily to the misdiagnosis and underdiagnosis of neurological diseases.

The resulting misdiagnosis of such diseases has far-reaching implications that greatly impact the ability of patients to receive appropriate treatments in the proper therapeutic window.

Altoida: Pioneering the Next Generation of Diagnostic Tools

At Altoida, we are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.

By completing a series of augmented reality and motor activities designed to simulate complex ADLs on a smartphone or tablet, Altoida’s device extracts and provides new and robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores.

This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. After our Breakthrough Device designation by the FDA, Altoida’s device will provide patients with a predictive score that will enable a highly accurate prediction of whether a patient aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease.

When this score is taken in conjunction with our neurocognitive domain scores, providers will be able to make specific, personalized conclusions about how neurological diseases are uniquely affecting their patients. This, in turn, will enable a personalized precision approach to treatment and care plan development for neurological disease patients.

To learn more about hippocampal atrophy in Alzheimer’s disease or about Altoida’s Precision Neurology platform and medical device, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
@ Altoida 2021